MLPA® Kits

For a description how to create and adapt MLPA Kits, that are not available on this page, please have a look at our User Manual MLPA.

Import of SALSA MLPA® kit descriptions via the SEQUENCE Pilot operation "Mixes [master file] / button [Import]".

Mix
Version
Date
Region
Application
Vs. 29
04-03-2012
SMN1, SMN2, 5q13 Spinal Muscular Atrophy (SMA)
Vs. 30 20-12-2012 SMN1, SMN2, 5q13 Spinal Muscular Atrophy (SMA)
Vs. 31 13-07-2013 SMN1, SMN2, 5q13 Spinal Muscular Atrophy (SMA)
Vs. 33 03-07-2015 SMN1, SMN2, 5q13 Spinal Muscular Atrophy (SMA)
P021-A2 Vs. 34 13-04-2016 SMN1, SMN2, 5q13 Spinal Muscular Atrophy (SMA)
P021-A2 Vs. 35 10-01-2017 SMN1, SMN2, 5q13 Spinal Muscular Atrophy (SMA)
P021-A2 Vs. 38 11-08-2017 SMN1, SMN2, 5q13 Spinal Muscular Atrophy (SMA)
Vs. 10
08-11-2010
PLP1 Xq22 Pelizaeus-Merzbacher disease (PMD)
P022-B1 Vs. 11 15-03-2012 PLP1 Xq22 Pelizaeus-Merzbacher disease (PMD)
P022-B1 Vs. 12 20-12-2012 PLP1 Xq22 Pelizaeus-Merzbacher disease (PMD)
P022-B2 Vs. 14 16-01-2015 PLP1 Xq22 Pelizaeus-Merzbacher disease (PMD)
Vs. 09
20-11-2006
22q11 DiGeorge syndrome, Velocardiofacial syndrome (VCFS), Cat eye syndrome (CES)
Vs. 16
10-06-2008
22q11 DiGeorge syndrome, Velocardiofacial syndrome (VCFS), Cat eye syndrome (CES)
Vs. 11
05-05-2008
CDKN2A / 2B region Various types of tumors
Vs. 03
20-11-2006
ASPA, 17p13 Canavan disease
Vs. 09
14-02-2010
ASPA, 17p13 Canavan disease
Vs. 11
20-12-2012
ASPA, 17p13 Canavan disease
Vs. 12
16-05-2014
ASPA, 17p13 Canavan disease
Vs. 05
15-08-2011
NSD1, 5q35 Sotos syndrome
Vs. 06
14-03-2012
NSD1, 5q35 Sotos syndrome
Vs. 07
26-11-2012
NSD1, 5q35 Sotos syndrome
Vs. 08
21-11-2013
NSD1, 5q35 Sotos syndrome
Vs. 10
21-01-2015
NSD1, 5q35 Sotos syndrome
Vs. 11
08-03-2017
NSD1, 5q35 Sotos syndrome
Vs. 08
26-06-2008
1p, 3, 6p, 8q (MYC region) Uveal Melanoma
Vs. 11
12-08-2011
1p, 3, 6p, 8q (MYC region) Uveal Melanoma
Vs. 14
24-04-2013
1p, 3, 6p, 8q (MYC region) Uveal Melanoma
P028-A1 Vs. 01 03-12-2012 UNC13D 17q25.1, PRF1 10q22.1, STX11 6q24.2 Familial lymphohistiocytosis (HLH)
P028-B1 Vs. 03 19-01-2016 UNC13D 17q25.1, PRF1 10q22.1, STX11 6q24.2 Familial lymphohistiocytosis (HLH)
Vs. 07
13-11-2009
WBS criticial region 7q11.23 Williams-Beuren syndrome
Vs. 09
04-03-2012
WBS criticial region 7q11.23 Williams-Beuren syndrome
Vs. 10
21-12-2012
WBS criticial region 7q11.23 Williams-Beuren syndrome
Vs. 14
04-12-2015
WBS criticial region 7q11.23 Williams-Beuren syndrome
Vs. 15
10-01-2017
WBS criticial region 7q11.23 Williams-Beuren syndrome
Vs. 16
29-05-2017
WBS criticial region 7q11.23 Williams-Beuren syndrome
Vs. 12
12-09-2011
FANCA 16q24.3 Fanconi Anemia (FA)
Vs. 13
27-04-2012
FANCA 16q24.3 Fanconi Anemia (FA)
P031-B1 Vs. 14 21-12-2012 FANCA 16q24.3 Fanconi Anemia (FA)
Vs. 15
12-08-2015
FANCA 16q24.3 Fanconi Anemia (FA)
Vs. 16
11-02-2016
FANCA 16q24.3 Fanconi Anemia (FA)
Vs. 17
10-01-2017
FANCA 16q24.3 Fanconi Anemia (FA)
Vs. 12
12-09-2011
FANCA 16q24.3 Fanconi Anemia (FA)
Vs. 13
27-04-2012
FANCA 16q24.3 Fanconi Anemia (FA)
Vs. 15
12-08-2015
FANCA 16q24.3 Fanconi Anemia (FA)
Vs. 16
11-02-2016
FANCA 16q24.3 Fanconi Anemia (FA)
Vs. 17
10-01-2017
FANCA 16q24.3 Fanconi Anemia (FA)
Vs. 21
27-02-2012
CMT1/HNPP region, 17p11.2 Charot-Marie Tooth disease (CMT1), Hereditary Neuropathy with liability to Pressure Palsies (HNPP)
P033-B3 Vs. 22 12-09-2012 CMT1/HNPP region, 17p11.2 Charot-Marie Tooth disease (CMT1), Hereditary Neuropathy with liability to Pressure Palsies (HNPP)
P033-B3 Vs. 23 26-12-2012 CMT1/HNPP region, 17p11.2 Charot-Marie Tooth disease (CMT1), Hereditary Neuropathy with liability to Pressure Palsies (HNPP)
P033-B3 Vs. 24 26-03-2015 CMT1/HNPP region, 17p11.2 Charot-Marie Tooth disease (CMT1), Hereditary Neuropathy with liability to Pressure Palsies (HNPP)
P033-B4 Vs. 25 28-09-2015 CMT1/HNPP region, 17p11.2 Charot-Marie Tooth disease (CMT1), Hereditary Neuropathy with liability to Pressure Palsies (HNPP)
P033-B4 Vs. 01 24-06-2016 CMT1/HNPP region, 17p11.2 Charot-Marie Tooth disease (CMT1), Hereditary Neuropathy with liability to Pressure Palsies (HNPP)
P034-B1 Vs. 29 20-12-2013 DMD, Xp21.2 Duchene Muscular Dystrophy (DMD)
P034-B2 Vs. 30 25-05-2015 DMD, Xp21.2 Duchene Muscular Dystrophy (DMD)
P034-B2 Vs. 31 05-02-2016 DMD, Xp21.2 Duchene Muscular Dystrophy (DMD)
P034-B2 Vs. B2/B1-01 11-05-2016 DMD, Xp21.2 Duchene Muscular Dystrophy (DMD)
P034-B2 Vs. B2/B1-02 10-02-2017 DMD, Xp21.2 Duchene Muscular Dystrophy (DMD)
P035-B1 Vs. 29 20-12-2013 DMD, Xp21.2 Duchene Muscular Dystrophy (DMD)
P035-B1 Vs. 30 25-05-2015 DMD, Xp21.2 Duchene Muscular Dystrophy (DMD)
P035-B1 Vs. 31 05-02-2016 DMD, Xp21.2 Duchene Muscular Dystrophy (DMD)
P035-B2 Vs. B2/B1-01 11-05-2016 DMD, Xp21.2 Duchene Muscular Dystrophy (DMD)
P035-B1 Vs. B2/B1-02 10-02-2017 DMD, Xp21.2 Duchene Muscular Dystrophy (DMD)
Vs. 10
30-11-2010
all subtelomeres Broad subtelomere screening
Vs. 13
07-03-2012
all subtelomeres Broad subtelomere screening
Vs. 15
01-03-2013
all subtelomeres Broad subtelomere screening
Vs. 16
04-10-2013
all subtelomeres Broad subtelomere screening
Vs. 18
31-07-2014
all subtelomeres Subtelomeric testing
Vs. E3-01
28-02-2017
all subtelomeres Subtelomeric testing
Vs. E3-02
14-12-2017
all subtelomeres Subtelomeric testing
Vs. 05
06-10-2006
various Chronic Lymphocytic Leukemia (CLL)
Vs. 14
30-06-2010
various Chronic Lymphocytic Leukemia (CLL)
P037-B1 Vs. 20 17-12-2013 various Chronic Lymphocytic Leukemia (CLL)
P037-B1 Vs. 21 27-10-2014 various Chronic Lymphocytic Leukemia (CLL)
Vs. 05
06-10-2006
various Chronic Lymphocytic Leukemia (CLL)
Vs. 14
30-06-2010
various Chronic Lymphocytic Leukemia (CLL)
P038-B1 Vs. 20
17-12-2013
various Chronic Lymphocytic Leukemia (CLL)
P038-B1 Vs. 21 27-10-2014 various Chronic Lymphocytic Leukemia (CLL)